Lifetime	lifetime	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
mice	mice	O	O	O	O
with	with	O	O	O	O
azidothymidine	azidothymidine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
AZT	azt	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
produces	produces	O	O	O	O
myelodysplasia	myelodysplasia	O	O	OTHERS	I
.	.	O	O	O	O

AZT	azt	CHEMICALS	O	OTHERS	I
has	has	O	O	O	O
induced	induced	O	O	O	O
a	a	O	O	O	O
macrocytic	macrocytic	O	O	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
AIDS	aids	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
on	on	O	O	O	O
long	long	O	O	O	O
term	term	O	O	O	O
AZT	azt	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
is	is	O	O	O	O
generally	generally	O	O	O	O
assumed	assumed	O	O	O	O
that	that	O	O	O	O
DNA	dna	O	O	O	O
elongation	elongation	O	O	O	O
is	is	O	O	O	O
stopped	stopped	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
insertion	insertion	O	O	O	O
of	of	O	O	O	O
AZT	azt	CHEMICALS	O	OTHERS	I
into	into	O	O	O	O
the	the	O	O	O	O
chain	chain	O	O	O	O
in	in	O	O	O	O
place	place	O	O	O	O
of	of	O	O	O	O
thymidine	thymidine	O	O	OTHERS	I
thus	thus	O	O	O	O
preventing	preventing	O	O	O	O
the	the	O	O	O	O
phosphate	phosphate	CHEMICALS	O	OTHERS	I
hydroxyl	hydroxyl	O	O	OTHERS	I
linkages	linkages	O	O	O	O
and	and	O	O	O	O
therefore	therefore	O	O	O	O
suppresses	suppresses	O	O	O	O
hemopoietic	hemopoietic	O	O	O	O
progenitor	progenitor	O	O	O	O
cell	cell	O	O	O	O
proliferation	proliferation	O	O	O	O
in	in	O	O	O	O
an	an	O	O	O	O
early	early	O	O	O	O
stage	stage	O	O	O	O
of	of	O	O	O	O
differentiation	differentiation	O	O	O	O
.	.	O	O	O	O

CBA/Ca	cba/ca	O	O	O	O
male	male	O	O	O	O
mice	mice	O	O	O	O
started	started	O	O	O	O
on	on	O	O	O	O
AZT	azt	CHEMICALS	O	OTHERS	I
0.75	0.75	O	O	O	O
mg/ml	mg/ml	O	O	O	O
H2O	h2o	CHEMICALS	O	OTHERS	I
at	at	O	O	O	O
84	84	O	O	O	O
days	days	O	O	O	O
of	of	O	O	O	O
age	age	O	O	O	O
and	and	O	O	O	O
kept	kept	O	O	O	O
on	on	O	O	O	O
it	it	O	O	O	O
for	for	O	O	O	O
687	687	O	O	O	O
days	days	O	O	O	O
when	when	O	O	O	O
dosage	dosage	O	O	O	O
reduced	reduced	O	O	O	O
to	to	O	O	O	O
0.5	0.5	O	O	O	O
mg/ml	mg/ml	O	O	O	O
H2O	h2o	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
a	a	O	O	O	O
group	group	O	O	O	O
,	,	O	O	O	O
another	another	O	O	O	O
group	group	O	O	O	O
removed	removed	O	O	O	O
from	from	O	O	O	O
AZT	azt	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
see	see	O	O	O	O
recovery	recovery	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
third	third	O	O	O	O
group	group	O	O	O	O
remained	remained	O	O	O	O
on	on	O	O	O	O
0.75	0.75	O	O	O	O
mg	mg	O	O	OTHERS	I
.	.	O	O	O	O

At	at	O	O	O	O
687	687	O	O	O	O
days	days	O	O	O	O
mice	mice	O	O	O	O
that	that	O	O	O	O
had	had	O	O	O	O
been	been	O	O	O	O
on	on	O	O	O	O
0.75	0.75	O	O	O	O
mg	mg	O	O	OTHERS	I
had	had	O	O	O	O
average	average	O	O	O	O
platelet	platelet	O	O	O	O
counts	counts	O	O	O	O
of	of	O	O	O	O
2.5	2.5	O	O	O	O
x	x	O	O	O	O
10(6	10(6	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Histological	histological	O	O	O	O
examination	examination	O	O	O	O
on	on	O	O	O	O
9	9	O	O	O	O
of	of	O	O	O	O
10	10	O	O	O	O
mice	mice	O	O	O	O
with	with	O	O	O	O
such	such	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
showed	showed	O	O	O	O
changes	changes	O	O	O	O
compatible	compatible	O	O	O	O
with	with	O	O	O	O
myelodysplastic	myelodysplastic	O	O	OTHERS	I
syndrome	syndrome	O	O	OTHERS	I
(	(	O	O	O	O
MDS	mds	O	O	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
variety	variety	O	O	O	O
of	of	O	O	O	O
histological	histological	O	O	O	O
patterns	patterns	O	O	O	O
was	was	O	O	O	O
observed	observed	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
were	were	O	O	O	O
two	two	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
hypocellular	hypocellular	O	O	O	O
myelodysplasia	myelodysplasia	O	O	OTHERS	I
,	,	O	O	O	O
two	two	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
hypersegmented	hypersegmented	O	O	O	O
myelodysplastic	myelodysplastic	O	O	OTHERS	I
granulocytosis	granulocytosis	O	O	O	O
,	,	O	O	O	O
two	two	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
hypercellular	hypercellular	O	O	O	O
marrow	marrow	O	O	O	O
with	with	O	O	O	O
abnormal	abnormal	O	O	O	O
megakaryocytes	megakaryocytes	O	O	O	O
with	with	O	O	O	O
bizarre	bizarre	O	O	O	O
nuclei	nuclei	O	O	O	O
,	,	O	O	O	O
one	one	O	O	O	O
case	case	O	O	O	O
of	of	O	O	O	O
megakaryocytic	megakaryocytic	O	O	O	O
myelosis	myelosis	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
hyperplastic	hyperplastic	O	O	OTHERS	I
marrow	marrow	O	O	OTHERS	I
,	,	O	O	O	O
dysmyelopoiesis	dysmyelopoiesis	O	O	OTHERS	I
and	and	O	O	O	O
a	a	O	O	O	O
hypocellular	hypocellular	O	O	OTHERS	I
marrow	marrow	O	O	OTHERS	I
and	and	O	O	O	O
two	two	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
myelodysplasia	myelodysplasia	O	O	OTHERS	I
with	with	O	O	O	O
dyserythropoiesis	dyserythropoiesis	O	O	OTHERS	I
,	,	O	O	O	O
hemosiderosis	hemosiderosis	O	O	OTHERS	I
and	and	O	O	O	O
a	a	O	O	O	O
hypocellular	hypocellular	O	O	OTHERS	I
marrow	marrow	O	O	OTHERS	I
.	.	O	O	O	O

Above	above	O	O	O	O
mentioned	mentioned	O	O	O	O
AZT	azt	CHEMICALS	O	OTHERS	I
incorporation	incorporation	O	O	O	O
may	may	O	O	O	O
have	have	O	O	O	O
induced	induced	O	O	O	O
an	an	O	O	O	O
ineffective	ineffective	O	O	O	O
hemopoiesis	hemopoiesis	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
primitive	primitive	O	O	O	O
hemopoietic	hemopoietic	O	O	O	O
progenitor	progenitor	O	O	O	O
cells	cells	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
is	is	O	O	O	O
known	known	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
seen	seen	O	O	O	O
commonly	commonly	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
myelodysplastic	myelodysplastic	O	O	OTHERS	I
syndrome	syndrome	O	O	OTHERS	I
.	.	O	O	O	O

